Back to top
more

If you wish to go to ZacksFunds.com, click OK. If you do not, click Cancel.

Rydex Srs Trust Biotechnology Fd: (MF: RYOIX)

(MF) As of Jul 27, 2015 06:06 PM ET

 Add to portfolio

$102.03 USD

-1.28 (-1.24%)

Zacks MF Rank : 3 - Hold [?]     3    

This is our Mutual Fund rating system that serves as a timeliness indicator for Mutual Fund's over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

Zacks Mutual Fund Rank FAQ - Learn more about the Zacks Mutual Fund Rank
Zacks Mutual Fund Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank

Latest Performance as of Jun 30, 2015

Total Return %* Percentile Rank Objective
YTD 22.64 11
3 months 7.65 12
6 months 22.64 11
1 Year 44.27 16
3 Year 38.68 14
5 Year 35.73 8
10 Year 18.62 9

* Annual for three years and beyond.

Zacks Premium Research for RYOIX

This is our Mutual Fund rating system that serves as a timeliness indicator for Mutual Fund's over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

Zacks Mutual Fund Rank FAQ - Learn more about the Zacks Mutual Fund Rank
Zacks Mutual Fund Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank

Zacks MF Rank [?] Hold 3
MF Research Report

Mutual Funds Research & Tools

Search Similar Mutual Funds

Research similar Mutual Funds with higher ranks and performance ratings.

Mutual Funds Comparison View (minimum of 2)

Mutual Funds Screener

Narrow down the universe of 18,000+ funds we rank with our robust, yet easy-to-use mutual fund screeners. Select from up to 50 different data points to find the mutual funds that best Screen meet your unique criteria.

Portfolio Statistics

%Unrealized Gain YTD 45.22
% Yield 0.00
% SEC Yield NA
Net Assets (Mil $) 6/30/2015 498.07
%Turnover 6/30/2015 107.00

Risk

3 Year 5 Year 10 Year
Beta 0.94 0.91 0.85
Alpha 21.62 19.07 12.11
R Squared 0.15 0.30 0.37
Std. Dev. 20.39 19.78 20.86
Sharpe 2.02 1.93 1.00

Sector / Country Weightings

As of 6/30/2015 % of Portfolio
Health 64.76
Services 20.92
Other 8.06
Technology 5.08
Industrial Cyclical 0.73
Retail Trade 0.45

Portfolio Holdings

Top Equity Holdings
(As of 3/31/2015)
% of Portfolio Value (Mil$)
GILEAD SCIENCES INC 6.78 46.88
AMGEN INC 6.08 42.06
BIOGEN INC 5.70 39.44
CELGENE CORP 5.32 36.80
REGENERON PHARMACEUTICALS 3.54 24.52
ALEXION PHARMACEUTICALS I 3.32 22.98
VERTEX PHARMACEUTICALS IN 2.88 19.90
ILLUMINA INC 2.82 19.52
BIOMARIN PHARMACEUTICAL 2.56 17.71

Stock Holding % of Net Assets

As Of 3/31/2015
Total Issues 78
Avg. P/E 34.20
Avg. P/Book 5.93
Avg. EPS Growth 16.41
Avg. Market Value (Mil $) 33,214

Allocation

% of Portfolio
Large Growth 19.61
Large Value 0.00
Small Growth 36.79
Small Value 0.00
Foreign Stock 0.00
Emerging Market 0.00
Precious Metal 0.00
Intermediate Bond 0.00
Foreign Bond 0.00
High Yield Bond 0.00